JP2008510006A - 化合物 - Google Patents

化合物 Download PDF

Info

Publication number
JP2008510006A
JP2008510006A JP2007527895A JP2007527895A JP2008510006A JP 2008510006 A JP2008510006 A JP 2008510006A JP 2007527895 A JP2007527895 A JP 2007527895A JP 2007527895 A JP2007527895 A JP 2007527895A JP 2008510006 A JP2008510006 A JP 2008510006A
Authority
JP
Japan
Prior art keywords
methyl
tetrahydro
benzimidazol
het
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007527895A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008510006A5 (cg-RX-API-DMAC7.html
Inventor
グトムンソン,クリスティアン
セバハール,ポール,リチャード
リチャードソン,リア,ドーロラ
Original Assignee
スミスクライン ビーチャム コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スミスクライン ビーチャム コーポレーション filed Critical スミスクライン ビーチャム コーポレーション
Publication of JP2008510006A publication Critical patent/JP2008510006A/ja
Publication of JP2008510006A5 publication Critical patent/JP2008510006A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2007527895A 2004-08-16 2005-08-12 化合物 Pending JP2008510006A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60192804P 2004-08-16 2004-08-16
PCT/US2005/028811 WO2006023400A2 (en) 2004-08-16 2005-08-12 Chemical compounds

Publications (2)

Publication Number Publication Date
JP2008510006A true JP2008510006A (ja) 2008-04-03
JP2008510006A5 JP2008510006A5 (cg-RX-API-DMAC7.html) 2008-10-02

Family

ID=35968075

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007527895A Pending JP2008510006A (ja) 2004-08-16 2005-08-12 化合物

Country Status (18)

Country Link
US (1) US20080045537A1 (cg-RX-API-DMAC7.html)
EP (1) EP1789045A2 (cg-RX-API-DMAC7.html)
JP (1) JP2008510006A (cg-RX-API-DMAC7.html)
KR (1) KR20070042568A (cg-RX-API-DMAC7.html)
CN (1) CN101039672A (cg-RX-API-DMAC7.html)
AR (1) AR050522A1 (cg-RX-API-DMAC7.html)
AU (1) AU2005277638A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0514438A (cg-RX-API-DMAC7.html)
CA (1) CA2577100A1 (cg-RX-API-DMAC7.html)
IL (1) IL181160A0 (cg-RX-API-DMAC7.html)
MA (1) MA28814B1 (cg-RX-API-DMAC7.html)
MX (1) MX2007001958A (cg-RX-API-DMAC7.html)
NO (1) NO20071161L (cg-RX-API-DMAC7.html)
PE (1) PE20060646A1 (cg-RX-API-DMAC7.html)
RU (1) RU2350604C2 (cg-RX-API-DMAC7.html)
TW (1) TW200619217A (cg-RX-API-DMAC7.html)
WO (1) WO2006023400A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200701282B (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010534713A (ja) * 2007-07-31 2010-11-11 バイエル・クロツプサイエンス・エス・アー 殺菌剤n−シクロアルキル−n−二環式−カルボキサミド誘導体
JP2011085891A (ja) * 2009-09-16 2011-04-28 Jsr Corp 液晶配向剤および液晶表示素子
JP2020535226A (ja) * 2017-09-25 2020-12-03 シージーンテック (スーチョウ, チャイナ) カンパニー リミテッド Cxcr4阻害剤としてのヘテロアリール化合物、それを用いた組成物及び方法

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7728026B2 (en) 2005-04-11 2010-06-01 Abbott Laboratories, Inc. 2-substituted-1 h-benzimidazile-4-carboxamides are PARP inhibitors
WO2007049771A1 (ja) 2005-10-28 2007-05-03 Ono Pharmaceutical Co., Ltd. 塩基性基を含有する化合物およびその用途
PT1961744E (pt) 2005-11-18 2013-05-15 Ono Pharmaceutical Co Composto que contém um grupo básico e sua utilização
US8618122B2 (en) 2006-05-16 2013-12-31 Ono Pharmaceutical Co., Ltd. Compound having acidic group which may be protected, and use thereof
WO2008016006A1 (fr) 2006-07-31 2008-02-07 Ono Pharmaceutical Co., Ltd. Composé auquel un groupe cyclique est lié par une liaison spiro et son utilisation
GB0702695D0 (en) * 2007-02-12 2007-03-21 Ark Therapeutics Ltd Production of vectors
WO2010098866A1 (en) 2009-02-27 2010-09-02 Supergen, Inc. Cyclopentathiophene/cyclohexathiophene dna methyltransferase inhibitors
JP5712524B2 (ja) * 2009-10-28 2015-05-07 Jsr株式会社 液晶配向剤および液晶表示素子
KR101594002B1 (ko) 2010-10-06 2016-02-15 글락소스미스클라인 엘엘씨 Pi3 키나제 억제제로서의 벤즈이미다졸 유도체
CN102675305B (zh) * 2011-03-08 2014-11-12 中国科学院上海药物研究所 一类咪唑并吡啶类化合物及其制备方法和用途
CN103570683B (zh) * 2012-07-30 2018-04-17 中国科学院上海药物研究所 多取代胺类化合物及其制备方法和用途
CN109069486A (zh) 2015-12-14 2018-12-21 X4 制药有限公司 治疗癌症的方法
CN109069426B (zh) 2015-12-14 2021-10-29 X4 制药有限公司 治疗癌症的方法
US10610527B2 (en) 2015-12-22 2020-04-07 X4 Pharmaceuticals, Inc. Methods for treating immunodeficiency disease
US11337969B2 (en) 2016-04-08 2022-05-24 X4 Pharmaceuticals, Inc. Methods for treating cancer
US10988465B2 (en) 2016-06-21 2021-04-27 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof
EP3808748B1 (en) 2016-06-21 2026-05-20 X4 Pharmaceuticals, Inc. Substituted piperidines as cxcr4-inhibitors
JP6994767B2 (ja) 2016-06-21 2022-01-14 エックス4 ファーマシューティカルズ, インコーポレイテッド Cxcr4阻害剤およびその使用
US11497744B2 (en) 2017-02-21 2022-11-15 Emory University Chemokine CXCR4 receptor modulators and uses related thereto
KR102678977B1 (ko) * 2017-09-25 2024-06-28 씨젠테크 (쑤저우, 차이나) 컴퍼니 리미티드 Cxcr4 저해제로서 헤테로아릴 화합물, 그 조성물 및 이용 방법
EP3768256A4 (en) 2018-03-19 2021-11-24 Emory University PAN-TROPICAL ENTRANCE INHIBITORS
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
CN115515585A (zh) 2020-03-10 2022-12-23 X4 制药有限公司 用于治疗中性粒细胞减少症的方法
WO2023003862A1 (en) 2021-07-19 2023-01-26 Emory University Cxcr4 modulators and uses related thereto

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003055876A1 (en) * 2001-12-21 2003-07-10 Anormed Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
JP2004508421A (ja) * 2000-09-15 2004-03-18 アノーメッド インコーポレイティド ケモカインレセプター結合性ヘテロ環式化合物
JP2004512336A (ja) * 2000-09-15 2004-04-22 アノーメッド インコーポレイティド ケモカインレセプター結合複素環式化合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2289581C2 (ru) * 2000-09-15 2006-12-20 Анормед, Инк. Гетероциклические соединения, содержащая их фармацевтическая композиция и их применение
KR20030034184A (ko) * 2000-09-15 2003-05-01 아노르메드 인코포레이티드 케모킨 수용체 결합 헤테로사이클릭 화합물
US7332605B2 (en) * 2004-03-15 2008-02-19 Anormed, Inc. Process for the synthesis of CXCR4 antagonist

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004508421A (ja) * 2000-09-15 2004-03-18 アノーメッド インコーポレイティド ケモカインレセプター結合性ヘテロ環式化合物
JP2004512336A (ja) * 2000-09-15 2004-04-22 アノーメッド インコーポレイティド ケモカインレセプター結合複素環式化合物
WO2003055876A1 (en) * 2001-12-21 2003-07-10 Anormed Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010534713A (ja) * 2007-07-31 2010-11-11 バイエル・クロツプサイエンス・エス・アー 殺菌剤n−シクロアルキル−n−二環式−カルボキサミド誘導体
US9102588B2 (en) 2007-07-31 2015-08-11 Philippe Desbordes Fungicide N-cycloalkyl-N-bicyclic-carboxamide derivatives
JP2011085891A (ja) * 2009-09-16 2011-04-28 Jsr Corp 液晶配向剤および液晶表示素子
JP2020535226A (ja) * 2017-09-25 2020-12-03 シージーンテック (スーチョウ, チャイナ) カンパニー リミテッド Cxcr4阻害剤としてのヘテロアリール化合物、それを用いた組成物及び方法
JP7282786B2 (ja) 2017-09-25 2023-05-29 シージーンテック (スーチョウ, チャイナ) カンパニー リミテッド Cxcr4阻害剤としてのヘテロアリール化合物、それを用いた組成物及び方法

Also Published As

Publication number Publication date
RU2007105823A (ru) 2008-09-27
PE20060646A1 (es) 2006-08-04
MX2007001958A (es) 2007-05-09
US20080045537A1 (en) 2008-02-21
EP1789045A2 (en) 2007-05-30
TW200619217A (en) 2006-06-16
NO20071161L (no) 2007-05-14
CA2577100A1 (en) 2006-03-02
AU2005277638A1 (en) 2006-03-02
RU2350604C2 (ru) 2009-03-27
CN101039672A (zh) 2007-09-19
BRPI0514438A (pt) 2008-06-10
IL181160A0 (en) 2007-07-04
MA28814B1 (fr) 2007-08-01
WO2006023400A2 (en) 2006-03-02
KR20070042568A (ko) 2007-04-23
WO2006023400A3 (en) 2006-06-08
AR050522A1 (es) 2006-11-01
ZA200701282B (en) 2010-05-26

Similar Documents

Publication Publication Date Title
RU2350604C2 (ru) Производные тетрагидрохинолина, демонстрирующие защитное от вич-инфекции действие
US12098130B2 (en) 1,4-substituted piperidine derivatives
US12157733B2 (en) Aminotriazolopyridines as kinase inhibitors
US10787450B2 (en) Spiro-fused cyclic ureas as inhibitors of rock
JP6728208B2 (ja) ベンザゼピンジカルボキサミド化合物
KR20190112047A (ko) Lsd1 억제제 및 그의 제조방법과 용도
US20080096861A1 (en) Chemical Compounds
JP2009524689A (ja) 化合物
EP3464274A1 (en) Benzazepine dicarboxamide compounds with secondary amide function
EP3080131A1 (en) Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
KR20070049682A (ko) 화합물
EP3847173B1 (en) Novel pyrazolopyridine compounds for the treatment of autoimmune disease
JP2008531716A (ja) 化合物
KR20220141331A (ko) P2x3 조정제
US20080200454A1 (en) Carbon-linked tetrahydro-pyrazolo-pyridine modulators of cathepsin s
WO2016100349A2 (en) Bicyclic azaheterocyclic compounds as nr2b nmda receptor antagonists
JP2008524255A (ja) 化学物質
KR20250121126A (ko) Irak3의 리간드 지정 분해제로서의 치환된 이미다조-기재 화합물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080808

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080808

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110906

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120221